drugset / Trial / NCT01003106
Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary Objective of this study is to evaluate the safety and tolerability of intraocular injections of 0.5mg or 2.0mg of ranibizumab in patients with macular edema due to retinal vein occlusion.
Timeline
- Start
- 2009-11
- Primary completion
- 2015-04
- Completion
- 2015-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |
| Subject | Ranibizumab | Monoclonal antibody | 2 mg | Intravitreal |